|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 severe or critically meta-analysis
|REMAP-CAP sarilumab, 2021|
|RCT||sarilumab||standard of care||COVID-19 severe or critically||some concern||48/402||conclusif|
|ARI-RAF (Della-Torre), 2020||OBS||sarilumab||control||COVID-19 severe or critically||NA||28/28||inconclusive|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).